재조합 인간 상피세포성장인자(DWP401)의 흰쥐에서의 약물동태

Pharmacokinetics Of Recombinant Human Epidermal Grouth Factor (DWP401) in Rats

Pharmacokinetics of DWP401, a recombinant human epidermal growth factor (rhEGF), was studied using radioimmunoassay (RIA) and 125I-DWP401 in rats. When DWP401 was administered i.v. at doses of 50 and 500 mcg/kg, the plasma DWP401 disappeared biiexponentially with terminal half life of 4.7 and 92.8 min. The Cmax and Tmax after s.c. administration of ti at doses of 50 and 500 mcg/kg were determined to be 23.6 and 17.5 ng/ml at 50 mcg/kg, and 261.4 ng/ml and 36.8 min, respectively. Both the total urinary and biliary recoveries of intact DWP401 2343 very low (<0.4%), probably due to its extensive degradation in the body. the concentration ratio of DWP401 between the organ and plasma decreased especially in the liver and kidney as the dose and time after the dose increased. For example, the liver/plasma and kidney/plasma concentration ratio of DWP401 at 2.5 min after i.v. doses of 50 mcg/kg were comparable and much larger than unity. But, the ratio at 2.5 min after i.v. doses of 500mcg/kg was much larger in the kidney that in than in the liver. These results suggest that the systemic administration of DWP401 might be subject to rapid and extensive clearance from circulation within several hour after main distrbution to liver and kidney.